



GENENTA EVOLVING INTO SAENTRA FORGE

The Next-Generation Strategic Industrial Consolidator
in Biotech, Defense, Aerospace, National Security.

FORWARD-LOOKING STATEMENTS AND OTHER NOTICES

Statements in this presentation contain “forward-looking statements,” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this presentation are forward-looking statements. Forward-looking statements contained in this presentation may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “suggest,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Genenta’s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict, including risks related to the transition to Saentra Forge, the expansion to a sovereign-aligned industrial consolidator, the legal proceedings with ENEA Tech, the funding provided by the recently acquired Mandatory Convertible Bond and related legal proceedings, the paused clinical trial for newly diagnosed GBM patients, as well as, Genenta’s ability to raise capital and/or establish partnerships to fund its research and development plans, etc. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” in Genenta's Annual Report on Form 20-F for the year ended December 31, 2025, and Genenta's material disclosures on Form 6-K dated October 10, 2025, January 26, 2026, as well as other Form 6-K disclosures filed with the Securities and Exchange Commission. Forward-looking statements contained in this document are made as of the date of this announcement, and Genenta undertakes no duty to update such information except as required under applicable law.

Non-GAAP Information. This document includes EBITDA (earnings before interest, taxes, depreciation, and amortization) which is a non-GAAP financial measure. EBITDA is defined as net loss adjusted to exclude interest income, income tax expense, and depreciation and amortization. This non-GAAP measure is not in accordance with, or an alternative for, measures prepared in accordance with generally accepted accounting principles (GAAP) and may be different from non-GAAP measures used by other companies. In addition, this non-GAAP measure is not based on any comprehensive set of accounting rules or principles. Genenta believes that this non-GAAP financial measure, when considered together with financial information prepared in accordance with US GAAP, can enhance investors’ and analysts’ ability to meaningfully compare its results from period to period and to forward-looking guidance, and to identify operating trends in its business. However, non-GAAP information is not superior to financial measures calculated in accordance with GAAP, is presented for supplemental informational purposes only, has limitations as an analytical tool, and should not be considered in isolation or as a substitute for financial information presented in accordance with US GAAP.

LEADERSHIP



PIERLUIGI PARACCHI
Chairman, CEO & Founder

He serves also as Chairman of **Fondazione Praexidia** and Chairman of **Praexidia Industrie Strategiche** (Euronext: PRXD). He is also Moderator of the **National Working Table for the Internationalization of the Biotechnology Sector**, promoted by the Italian Ministry of Foreign Affairs.

He serves on the Board of Guarantors of the **Italian Academy at Columbia University**. Previously, he founded and led **Quantica SGR**, co-founded **Axon Capital**, and served as Venture Consultant at **Sofinnova Partners**. He has also served on the Executive Committee of Federchimica-Assobiotec and is a Board Member of **InnovUp**.

+ 30 years of experience as Chief Financial Officer in various biopharmaceutical, diagnostic, and life science companies, including **Biological Dynamics**, **GenMark Diagnostics** (now part of Roche), and **C-N Biosciences** (now part of Merck). He also serves on the Board of Directors of several private high-technology companies, including **Nuclear RNA Networks**, an early-stage RNA gene transcription therapeutics company, and **Parabilis Space Technologies**, a global leader in hybrid solid-liquid rocket motors shaping the next era of responsive space operations. Raised \$500MM+ in equity and debt capital in public and private offerings. He holds a B.S. from the University of Pennsylvania (Wharton School), MBA from the University of Arizona (Eller School).

RICHARD B. SLANSKY
M.D., Ph.D., Board Member,
Chief Medical Officer and
Head of Development



FRANCESCO GALIMI
M.D., Ph.D., Board Member, serving
as Chief Medical Officer and Head of
Development

Dr. Galimi is a physician-executive with over 30 years of experience in healthcare R&D, including leadership roles in private and public biotech as well as large pharma companies. Most recently, he was Senior Vice President and Chief Medical Officer at **Adicet Bio**. Previously he served as Global Program General Manager at **Amgen**, Head of Clinical Development at **Onyx Pharmaceuticals**, and Executive Medical Leader at **GNF/Novartis**. Dr. Galimi holds an M.D. from the University of Torino Medical School with a specialty certification in Medical Oncology, and a Ph.D. in Oncology from the University of Torino Medical School. He conducted his post-doctoral research at the Salk Institute in La Jolla, California.

Highly experienced executive with skills in strategic finance, restructuring and reorganization processes, internal controls and corporate governance systems implementation. Prior to joining Genenta, she was Head of Finance at **OAM** – Financial Supervisory Authority, and she held CFO roles and was part of the Supervisory Body ex DLGS 231/01 of a public company in the renewable energy field. Former senior manager at **PWC**, in the industrial and service field. She earned a Master's degree at the University of Nicosia in Science of Digital Currency, a Degree as Strategic CFO at Harvard Business School, a Master's degree in Business and Administration at the University of Parma and she is a Chartered Public Accountant and Auditor.

BARBARA REGONINI
Finance Director



GIANFRANCO DE NIGRIS
Vice President Corporate
Development

Educated at Bocconi University and the Landon School of Economics, He began his career as an Equity Analyst Intern at **Kairos Partners SGR – Julius Baer Group**, before moving into investment banking at **NM Rothschild & Sons**. He subsequently gained experience in private banking and wealth management at **Mediobanca, Banor SIM and Banca Generali**. Since 2023, he has served as Vice President Corporate Development at Genenta Science (now Saentra Forge), where he manages relationships with global institutional investors, investment banks and analysts, partnering directly with the CEO.

GENENTA TRANSFORMING INTO SAENTRA FORGE

In response to evolving market dynamics and strategic opportunities, Genenta Science S.p.A. (Nasdaq: GNTA) is embarking on a strategic transformation to evolve into a **next-generation strategic industrial consolidator** focused on acquiring **privately held businesses** operating in national-security **regulated sectors** contemplated by the Italian Golden Power legislation¹.

The Company intends to target **majority ownership in companies with established operating profitability**, typically generating up to approximately €5 million in EBITDA.


In this context, Genenta plans to adopt the new corporate name of **Saentra Forge S.p.A.** with a new Nasdaq ticker symbol of **SAEN**².

1: Golden Power is Italy's investment screening framework — broadly comparable to CFIUS in the United States, the IEF regime in France, and the United Kingdom's NSI Act — and covers strategic domains such as biotechnology, biosecurity, defense, cybersecurity, AI-driven intelligence, aerospace, quantum technologies, secure communications, and critical infrastructure.

2: The new corporate name and the new Nasdaq ticker symbol pending effectiveness.

THE STRATEGIC PILLARS


The Company will be organized around key synergistic pillars



BIOTECHNOLOGY



DEFENSE




AEROSPACE




**NATIONAL
SECURITY**

built through strategic majority acquisitions, creating a diversified platform.



- DEFENSE
- AEROSPACE
- NATIONAL SECURITY




DEFENSE, AEROSPACE, NATIONAL SECURITY


Genenta's defense and advanced manufacturing pillar will be built through the acquisition of **multiple privately held businesses** operating across defense, aerospace and security sectors. Through this integration, the Company will seek to enhance these businesses through operational upgrades, institutional-grade governance, and improved financial visibility.

January 2026 first integration: ATC, an Italian company operating as **high-precision manufacturer of tactical rifles and special-forces weapon systems, and competition-grade sporting firearms.**

On March 27, 2026 Genenta announced that it has entered into a binding offer with **Sòphia High Tech S.r.l.**, (Sòphia HT) an Italian company manufacturing critical parts for Europe's space and defense programs. The transaction with Sòphia High Tech would be completed in two phases and remains subject to confirmatory due diligence, required approvals, and definitive transaction documentation.



- DEFENSE




ATC: COMPANY OVERVIEW

- ATC “Armi Tattiche Custom” is an Italian company **founded in 2019**. ATC designs, engineers, and manufactures **high-precision tactical rifles, chassis systems, optics mounts, bipods, and related accessories**. Through vertical integration of design and through final quality assurance, ATC provides fully customized, premium tactical systems. Its location in Northern Italy gives it access to advanced mechanical engineering talent and streamlined export logistics.
- ATC conducts its core operations in Italy, including R&D, CAD/CAM design, precision CNC machining, finishing, assembly, and final tomographic inspection.
- ATC holds UAMA, SeRNI export-control licenses, NATO qualifications and authorization from the Italian Ministry of Defense¹.
- They market under “**Made in Italy**” positioning, with the ability to deliver “custom” configurations to clients.
- ATC has established a commercial agreement in **Sofia (Bulgaria)** and is poised for the upcoming opening of a production plant in **Miami (USA)**.
- ATC products are used by special-forces units and include **combat-proven systems**. FY26 revenues are expected to be primarily driven by defense-related activities, including contracts with key institutional customers, notably in Ukraine.


¹: UAMA is the Italian government authority responsible for authorizing and overseeing the export and transfer of defense-related materials under applicable Italian and international regulations.

SeRNI: SeRNI, the Italian National Register of Defense and National Security Companies, certifies authorized defense and national security operators. North Atlantic Treaty Organization




ATC INTEGRATION: KEY FIGURES

- Genenta has entered into a binding agreement according to which it will provide funding for ATC through a **series of reserved capital increases, via a performance-based and staged acquisition** to support operations with the ultimate goal of owning a controlling position in ATC upon the achievement of defined performance milestones. The transaction has received the required clearance under the **Golden Power** regulatory framework. Genenta expects to fund a total of **EUR 5.1 million** in several performance-driven tranches.
- ATC is projecting **revenues** of approximately **€4.0 million in 2026**, increasing to around **€9.0 million by 2027**. The company operates with a **solid net cash position** and **no outstanding bank debt**, reflecting a disciplined management structure. On the profitability side, ATC forecasts **EBITDA** of more than **€2.0 million in 2026**, with management expecting EBITDA to approximately **double in 2027**.
- In addition, ATC anticipates closing 2026 with a positive cash balance exceeding €2.0 million and expects to further strengthen its liquidity position by ending 2027 with cash exceeding €5.0 million.




- AEROSPACE



SOPHIA HIGH TECH: COMPANY OVERVIEW

Sòphia HT S.r.l. is an Italian **aerospace and defense engineering and manufacturing** company. At its core, Sòphia HT builds the critical mechanical components of space and defense systems — the precision parts that hold rockets together, protect satellites in orbit, and allow aircraft to perform under extreme stress. The company covers the entire product lifecycle, from initial concept design and computer simulation, through prototyping and manufacturing, all the way to final testing, assembly, and qualification for flight. What sets Sòphia HT apart is its mastery of advanced manufacturing techniques — including **state-of-the-art metal 3D printing (known as Selective Laser Melting), CNC precision machining and multitasking, and the ability to work with some of the most demanding exotic materials in the industry, including titanium, Inconel, tungsten, and specialized copper alloys.** The company also conducts original materials research — developing entirely new metallic blends tailored to the specific demands of space propulsion. **Certified to the EN9100 aerospace quality standard and to ECSS-Q-ST-70-80C**, the ESA specification for additive manufacturing, Sòphia HT is one of the very few companies in Europe **qualified to 3D-print flight-ready space hardware to ESA and NASA standards.** With over 530 advanced projects completed, Sòphia HT serves leading European aerospace and defense organizations including **ESA, AVIO, Thales Alenia Space, Leonardo, MBDA, GSSI, and D-Orbit**, and also prestigious automotive brands such as **Lamborghini.**



SOPHIA HT INTEGRATION: KEY FIGURES


Genenta has entered into a binding offer with Sòphia HT an Italian company manufacturing critical parts for Europe's space and defense programs, under which Genenta will fund Sòphia HT through two reserved capital increases, with the goal of reaching a controlling stake upon the achievement of defined performance milestones. The transaction with Sòphia HT would be completed in two phases and remains subject to confirmatory due diligence, required approvals, and definitive transaction documentation.

Genenta expects to fund a total of EUR 6.0 million in two tranches, the second tranche being performance-driven. Sòphia HT is projecting growing revenues and operates with a solid net cash position, reflecting a disciplined management structure. Sòphia HT is already profitable and forecasts continued EBITDA growth in 2026, 2027 and beyond¹. The funds are expected to be used for materially scaling production capacity, accelerating technological differentiation, and strengthening commercial penetration².

¹ See "Non-GAAP Information" for a discussion of the measure EBITDA

² For additional information, please refer to our Form 6-K, filed with the Securities and Exchange Commission.

Genenta
Science



BIOTECHNOLOGY

GENENTA: DEVELOPING A POTENTIAL FIRST IN CLASS CELL THERAPY



Proprietary platform to provide durable and safe treatments for solid tumors

Temferon™ is a one-time cell therapy designed to break the tumor-induced immune suppression by enabling sustained targeted expression of **therapeutic payload inside the tumor microenvironment (TME)**.



Generating clinical proof of concept for breaking immune tolerance

TEM GBM Phase 1/2a study:

- **Phase 1 dosing completed** with 25 patients receiving Temferon.
- Favorable initial evidence of reprogramming of the tumor microenvironment.
- Potential ability to activate T cells which could then be enhanced by the use of immune checkpoint inhibitors.
- **Two patients** have been enrolled in the **TEM-LT long-term follow-up study, surviving three years** from the time of 1st surgery.

SURVIVAL METRICS IN TEM-GBM STUDY UP TO 3 YEARS

Evaluable Patients Dosed with Temferon	25
Number of Patients survival > 1 year	19 (76%)
Number of Patients survival > 2 years ¹	8 (32%)
Number of Patients survival > 3 years	2 (8%)

Survival rate at 1 and 2 years since first surgery compared favorably with reference GBM Italian registry data² (56.4% alive at 1 year, 14.4% alive at 2 years), indicating a potential survival benefit in the TEM-GBM treated cohort.

1 – Data as of January 20, 2026.

2 – Tumor registry of Istituto Nazionale Carlo Besta, Italy - Courtesy of Dr. Eoli.

PARTNERSHIPS TO TAKE TO THE NEXT STAGE




PARTNERSHIPS TO TAKE TO THE NEXT STAGE


The Company has reached **key clinical milestones** that it believes will now enable the advancement of its cell therapy platform through partnerships with leading pharmaceutical and biotech companies, with the potential to accelerate development, market access, and strategic value. **DC Advisory** has been engaged to serve as the Company's **exclusive financial advisor for partnership initiatives**. Such initiatives are envisaged to prioritize leveraging the technology platform for broader applications and indications, particularly in solid tumors that are inherently difficult to target, while pursuing combination therapy approaches, or continuing development of Temferon as a glioblastoma multiforme (GBM) monotherapy. During this process, the Company will continue to advance its trial in GBM, pursue a **capital-efficient approach** to advancing additional opportunities through partnerships and does not plan to internally advance the GU study and other clinical trials at this time.

HARNESSING THE POWER OF STEM CELLS WHILE INCORPORATING miRNA

Tie2-Expressing Monocytes (TEMs)




- Pro tumoral associated macrophage subset.
- Perivascular localization.
- Angiogenic & tissue remodeling function.
- Genetic ablation curbs tumor growth.



TEMFERON DELIVERS IFN- α WITHIN THE TUMOR MICROENVIRONMENT

Single Temferon treatment potentially renders solid tumors visible to the immune system



TEMFERON AT A GLANCE

TEMFERON

Frozen autologous hematopoietic stem and progenitor cells (CD34+) transduced ex-vivo with a third generation LVV to drive myeloid-specific IFN- α 2 expression.

FORMULATION

Cryopreserved intravenous injectable solution.

DURABILITY OF RESPONSE

Potentially life-long.

PLATFORM PROOF-OF-CONCEPT INDICATION

Solid tumors: μ MGMT GBM.


MECHANISM OF ACTION

Direct: anti-proliferative, anti-angiogenic;
Indirect: immune system re-programming, CD8+ T cells recruitment, T cells exhaustion counteraction.

TEMFERON: OVERCOMING IMMUNO-ONCOLOGY BARRIERS VIA TARGETED, TUMOR-AGNOSTIC IMMUNE ACTIVATION

DEMONSTRATED DURABILITY


CD14




HSCs enable the maintenance of a potential **long-term tumor protection** by creating a **life-long drug reservoir**.

SELECTIVE DELIVERY WITHIN THE TUMOR MICROENVIRONMENT

Tie2 macrophages (TEMs)



Recruited into Tumors




*De Palma et al. Nature Med 2003;
De Palma et al. Cancer Cell 2005 & 2008
Pucci et al. Blood 2009
Mazzei et al. Cancer Cell 2011*

TEMs, being recruited by growing tumors, enable the **payload delivery** within the TME.

PREVENT SYSTEMIC TOXICITY


Peripheral Blood



The miRNA post-transcriptional regulation limits the systemic **payload exposure**.

ACTIVATE IMMUNE SYSTEM

Genenta cell-based platform (IFN- α)



IFN- α deployment by TEMs, both in **pre-clinical and clinical** setting favors the **myeloid proinflammatory state**.

PRELIMINARY **CLINICAL DATA** IN μ MGMT GBM






SAFETY AND TOLERABILITY

- Detectable and expectedly very **low levels of IFN- α** (pg/ml range) in plasma;
- **Manageable safety profile**, with adverse events commonly associated with autologous stem cell transplantation and glioblastoma;
- **No dose limiting toxicities** observed to date;
- Rapid engraftment and **hematological recovery** observed in all patients treated (n=25).



BIOLOGICAL ACTIVITY

- Temferon-derived cells were **detectable** at more than 24 months **post infusion**;
- **Temferon** progeny detected **inside the GBM** tumor;
- Intra-tumor **IFN- α release**;
- Evidence of a pro-inflammatory state in recurrent tumors from patients who underwent second surgery;
- **Reprogramming** of the myeloid compartment.



PIERLUIGI PARACCHI, CEO

pierluigi.paracchi@genenta.com

www.genenta.com

Via dell'Annunciata 31 - 20121 Milan, Italy



APPENDIX

BOARD OF DIRECTORS



PIERLUIGI PARACCHI
Chairman, CEO & Founder

He serves also as Chairman of **Fondazione Praexidia** and Chairman of **Praexidia Industrie Strategiche** (Euronext: PRXD). He is also Moderator of the **National Working Table for the Internationalization of the Biotechnology Sector**, promoted by the Italian Ministry of Foreign Affairs.

He serves on the Board of Guarantors of the **Italian Academy at Columbia University**.

Previously, he founded and led **Quantica SGR**, co-founded **Axon Capital**, and served as Venture Consultant at **Sofinnova Partners**. He has also served on the Executive Committee of Federchimica-Assobiotech and is a Board Member of **InnovUp**.

Dr. Galimi is a physician-executive with over 30 years of experience in healthcare R&D, including leadership roles in private and public biotechs as well as large pharma companies.

Most recently, he was Senior Vice President and Chief Medical Officer at **Adicet Bio**.

Previously he served as Global Program General Manager at **Amgen**, Head of Clinical Development at **Onyx Pharmaceuticals**, and Executive Medical Leader at GNF/Novartis.

Dr. Galimi holds an M.D. from the University of Torino Medical School with a specialty certification in Medical Oncology, and a Ph.D. in Oncology from the University of Torino Medical School. He conducted his post-doctoral research at the Salk Institute in La Jolla, California.

FRANCESCO GALIMI
M.D., Ph.D., Board Member, serving as Chief Medical Officer and Head of Development



MIGUEL M. MUTTI
Board member

Senior executive with over 25 years of international experience in the pharmaceutical and investment banking sectors. He has a proven track record in corporate and business development, M&A, licensing, and general management, having led major growth, restructuring, and integration projects across Europe, Latin America, and Asia.


Currently, he serves as Managing Partner at **Sinergetica Healthcare**, a strategic consulting and investment firm focused on pharma, biotech, and medtech. Before that, he held senior leadership roles at **Lupin Limited**, **Grünenthal GmbH**, **Chemo Group**, and **Citigroup**.

Miguel combines strategic vision, financial expertise, and hands-on operational leadership, supported by an MBA from ISTUD and executive training at INSEAD.

Giacomo Paracchi is a Partner at **LEXIA**. His work primarily focuses on corporate law, commercial contracts and corporate governance, drawing on extensive experience both as a non-practising attorney and as **General Counsel** to major public and private multinational companies.

He has developed significant expertise across a wide range of industry sectors, including telecommunications, logistics, infrastructure, oil & gas, energy, pharmaceuticals and biotechnology. Giacomo is a member of the **Advisory Board** of the **Università Cattolica del Sacro Cuore** (Milan) for the **Executive Advanced Training programme in Corporate Compliance & Business Integrity**.

GIACOMO PARACCHI
Board member



ARMON R. SHAREI
Ph.D., Board Member

Armon is Founder and CEO of **Portal Biotechnologies** and formerly CEO and Founder of **SQZ Biotechnologies** (NYSE: SQZ).

He led company from invention to post-IPO with over \$300M in equity financing, \$1Bn **Roche** collaboration, and three clinical trials.

Stanford University, CA BS, with Honors and Distinction in Chemical Engineering and a Ph.D. in Chemical Engineering from Massachusetts Institute of Technology. Post-Doctoral Fellow, Immunology at Harvard Medical School.

ADVISOR



PAOLO SALVATO

ATC Board member and Genenta
Science advisor

Paolo Salvato is part of **ATC's Board of Directors** and he serves as **Genenta Science advisor**.

Mr. Salvato previously served as Chief Executive Officer of **Fiocchi Munizioni S.p.A. (CSG Group)**, where he led operational strengthening, international growth initiatives, and strategic positioning within the global defense ecosystem. He brings more than two decades of experience across defense industrial operations, with expertise spanning manufacturing execution, export markets, supply chain management, and regulatory compliance. Prior to Fiocchi Munizioni, he served as Chief Executive Officer of **Thales Italia**, and he held senior leadership roles at **Leonardo S.p.A.**, deepening his experience across the European defense and aerospace ecosystem.

FINANCIAL PROFILE



Cash & cash equivalents and marketable securities ¹	\$ 33 MM
Expected cash runway ²	More than 12 months
Number of shares outstanding ³	23.4 MM
Average volume ⁴	721K shares

1 – December 31, 2025.

2 – For additional information see the Company's Form 20-F filed with the SEC on March 31, 2026.

3 – As of December 31, 2025.

4 - At December 31, 2025 according to Yahoo Finance's key statistics listing.